OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes,provides the following unaudited preliminary revenue figures for the first six months ended 30 June
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused
Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000
Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia
Tribal secures £17m contract for next-generation student management system
MelodyVR Group PLC (AIM: MVR), the leading immersive live music platform, is set to launch in Singapore in partnership with The Singtel Group (“Singtel”), Asia’s leading communications technology company boasting
OptiBiotix Health plc, the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and cardiovascular health, is now in a pivotal position.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces the appointment of Aneta Zlotkowska as Head of Quality & Operations.
FDA Investigational New Drug authorisation for product containing LPLDL®
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare,announces it has entered into an exclusive distribution agreement for SlimBiome® Medical
